AVE1625: Clinical Trials

2 trials of AVE1625, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated. 2 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 22Completed 1, Terminated 1
Phase 11Completed 1

Follow AVE1625: new trials by email Literature Review of AVE1625 trials Research Report on AVE1625

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Efficacy and Safety of AVE1625 as a Co-treatment With Antipsychotic Therapy in Schizophrenia
AVE1625, placebo - Schizophrenia
Phase 2TerminatedSanofi8732007-02-012016-05-18
Activity of AVE1625 in Mild to Moderate Alzheimer's Patients.
AVE1625 - Alzheimer Disease
Phase 1 / Phase 2CompletedSanofi1622006-09-012008-12-19

Conditions studied

Alzheimer Disease (1)  ·  Schizophrenia (1)

Sponsors

Sanofi (2)

Countries

United States (2)  ·  Canada (1)  ·  France (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Sweden (1)

Results publications

PMID 28433500